author-photo

Soo-Young Choi

Catholic University of Korea

60

Papers

596

Citations

Citation Trend

Filter By

Papers (60) Sort By

Journal Conference Others

AMD1 is required for the maintenance of leukemic stem cells and promotes chronic myeloid leukemic growth.

2020 Oncogene
Show All
- Source
- Cite
- Save
Citations (3)
Optimal Time Points for BCR-ABL1 Tyrosine Kinase Domain Mutation Analysis on the Basis of European LeukemiaNet Recommendations in Chronic Myeloid Leukemia

2019 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
Compound mutations involving T315I and P-loop mutations are the major components of multiple mutations detected in tyrosine kinase inhibitor resistant chronic myeloid leukemia

2019 Leukemia Research
Show All
- Source
- Cite
- Save
Citations (4)
GCA links TRAF6-ULK1-dependent autophagy activation in resistant chronic myeloid leukemia

2019 Autophagy
Show All
- Source
- Cite
- Save
Citations (17)
Comprehensive analyses of safety and efficacy toward individualizing imatinib dosage in patients with chronic myeloid leukemia.

2019 International Journal of Hematology
Show All
- Source
- Cite
- Save
Citations (1)
Baseline BCR-ABL1 transcript type of e13a2 and large spleen size are predictors of poor long-term outcomes in chronic phase chronic myeloid leukemia patients who failed to achieve an early molecular response after 3 months of imatinib therapy

2018 Leukemia & Lymphoma
Show All
- Source
- Cite
- Save
Citations (6)
The accuracies of abdominal computed tomography and the neutrophil-to-lymphocyte ratio used to predict the development of clinically severe acute cholecystitis in elderly patients visiting an emergency department

2018 Nigerian Journal of Clinical Practice
Show All
- Source
- Cite
- Save
Citations (2)
BCR‐ABL1 transcript levels at 4 weeks have prognostic significance for time‐specific responses and for predicting survival in chronic‐phase chronic myeloid leukemia patients treated with various tyrosine kinase inhibitors

2018 Cancer Medicine
Show All
- Source
- Cite
- Save
Citations (4)
Prognostic Implication of Early Molecular Response at 3 Months in Chronic Myeloid Leukemia Patients: A Comparison of Imatinib and Second Generation Tyrosine Kinase Inhibitors

2018 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Comparative analyses of nilotinib versus high-dose imatinib versus sustained standard-dose imatinib in patients with chronic phase chronic myeloid leukemia following suboptimal molecular response to first-line imatinib

2018 Leukemia Research
Show All
- Source
- Cite
- Save
Citations (3)